ArticleCancer cell international2026
An integrative framework combining Mendelian randomization, single-cell profiling, and experimental validation identifies FTMT as a mitochondrial-immune regulator in non-small cell lung cancer.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMitochondrial iron handling and immune surveillance are intertwined in tumor biology. Mitochondrial ferritin (FTMT) buffers redox-active iron in mitochondria, while MICB is an NKG2D ligand that can promote anti-tumor cytotoxicity when expressed on tumor cells. However, whether FTMT has a causal relationship with non-small cell lung cancer (NSCLC) risk-and how this might connect to MICB biology-remains uncertain.
methodsWe applied a genetics-omics-validation workflow. We conducted two-sample Mendelian randomization (MR) and mediation MR using plasma proteomic pQTL summary statistics (UK Biobank Pharma Proteomics Project) and NSCLC GWAS summary statistics from FinnGen (R12). To contextualize results in the tumor microenvironment, we interrogated single-cell RNA-seq datasets via TISCH2 and explored pharmacogenomic associations using GDSC. Mechanistic plausibility was tested in A549 lung adenocarcinoma cells using FTMT overexpression followed by qPCR and Western blotting.
resultsGenetically predicted higher FTMT levels were associated with reduced NSCLC risk (IVW OR per 1-SD increase ≈ 0.91). Mediation MR suggested that MICB-related signals accounted for a modest proportion of the FTMT effect. Single-cell analyses showed FTMT enrichment in malignant epithelial cells, whereas MICB was expressed across multiple compartments. In vitro, FTMT overexpression increased MICB mRNA and protein abundance.
conclusionsIntegrating genetic evidence, tumor-context transcriptomics, and cell-based validation supports FTMT as a protective factor for NSCLC and points to a mitochondrial-immune axis involving MICB. Observed differences between blood-based genetic proxies and tumor-cell experiments are consistent with context-dependent regulation (e.g., circulating MICB can reflect shedding, whereas tumor-cell MICB reflects surface stress-ligand programs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.